Immunic Therapeutics
New York, United States · Biotechnology · 84 employees
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has s
Funding history
- Funding Round — $400.0M — Feb 2026
- Funding Round — $80.0M — Jan 2024
- Funding Round — $60.0M — Oct 2022
Recent signals
- Apr 28, 2026: Immunic Appoints Michael A. Panzara as Chief Medical Officer
- Feb 13, 2026: Raised $400.0M
- Jul 09, 2024: Jason Tardio Joins Immunic as Chief Operating Officer and President
- Jan 19, 2024: Raised $80.0M
- Oct 10, 2022: Raised $60.0M
See plans & pricing → Track Immunic Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.